Keywords: oncology, cardiovascular, drugs, push, novartis, 2nd-qtr, results
Oncology and cardiovascular drugs push Novartis' 2nd-qtr results
Article | 25 July 2005
Leading Swiss pharmaceutical firm Novartis delivered a strong set of second-quarter 2005 results, with net earnings rising 9.2% to $1.65 billion, or $0.70 per ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
